AtriCure/$ATRC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About AtriCure
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
- Ticker
- $ATRC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,350
- Headquarters
- Mason, United States
- Website
- www.atricure.com
AtriCure Metrics
BasicAdvanced
$3.1B
290.51
$0.21
1.25
-
Price and volume
Market cap
$3.1B
Beta
1.25
52-week high
$63.00
52-week low
$25.36
Average daily volume
894K
Financial strength
Current ratio
4.218
Quick ratio
3.025
Long term debt to equity
0.138
Total debt to equity
0.144
Interest coverage (TTM)
2.29%
Profitability
EBITDA (TTM)
33.746
Gross margin (TTM)
76.30%
Net profit margin (TTM)
1.85%
Operating margin (TTM)
2.26%
Effective tax rate (TTM)
12.75%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
1.25%
Return on equity (TTM)
2.15%
Valuation
Price to earnings (TTM)
290.514
Price to revenue (TTM)
5.185
Price to book
6.03
Price to tangible book (TTM)
13.07
Price to free cash flow (TTM)
56.676
Free cash flow yield (TTM)
1.76%
Free cash flow per share (TTM)
1.081
Growth
Revenue change (TTM)
13.94%
Earnings per share change (TTM)
-127.45%
3-year revenue growth (CAGR)
15.92%
10-year revenue growth (CAGR)
14.86%
3-year earnings per share growth (CAGR)
-29.94%
10-year earnings per share growth (CAGR)
-15.67%
What the Analysts think about AtriCure
Analyst ratings (Buy, Hold, Sell) for AtriCure stock.
Analyst projections of the future price of AtriCure stock.
Bulls say / Bears say
Profitability improved sharply: AtriCure reported $9.0 million of net income and $27.3 million of adjusted EBITDA in the second quarter. It also raised its 2026 adjusted EBITDA outlook to $85–89 million and expects positive cash generation. (AtriCure)
AtriCure received European CE mark approval for its FLEX-Mini and PRO-Mini devices and planned to launch them in Europe later in 2026. Successful uptake could extend the growth of these newer products beyond the US. (SEC)
Minimally invasive ablation revenue fell 23.1% in the second quarter as physicians shifted towards pulsed-field ablation catheters. Continued substitution could leave this part of the portfolio under pressure. (SEC)
AtriCure says new competitors are developing rival products and procedures in its key markets. If they gain ground, the company could lose share or face pressure on prices and margins. (SEC)
The company expects its expanded manufacturing facilities to add cost burden in the second half of 2026, while faster clinical-trial activity is increasing research spending. These costs could slow the improvement in margins and earnings. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
AtriCure Financial Performance
Revenues and expenses
AtriCure Earnings Performance
Company profitability
Upcoming events
No upcoming events
AtriCure News
AllArticlesVideos
Funds containing AtriCure
AllUSDEURGBP
Fund name | Fund size | $ATRC weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.30% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.30% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.30% |
iShares Ageing Population$AGED | $953M | 0.28% |
iShares Ageing Population£AGES | $953M | 0.28% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.